Precautionary measures reduce risk of definite neuroleptic malignant syndrome in newly typical neuroleptic-treated schizophrenia inpatients

International Clinical Psychopharmacology

Volumn 18, Issue 3, 2003, Pages 147-149

  Shiloh, Roni ^a   Valevski, Avi ^a   Bodinger, Liron ^a   Misgav, Sagit ^b   Aizenberg, Dov ^a   Dorfman Etrog, Pnina ^a   Weizman, Abraham ^a,c   Munitz, Hanan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV COMMUNITY MENTAL HEALTH CENTER   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

Antipsychotic drug; Neuroleptic malignant syndrome; Schizophrenia

Indexed keywords

FLUPENTIXOL; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERPHENAZINE; SULPIRIDE; THIORIDAZINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK FACTOR; SCHIZOPHRENIA; THERMOREGULATION; TREATMENT PLANNING;

ADULT; ANTIPSYCHOTIC AGENTS; BODY TEMPERATURE; CREATINE KINASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PROGNOSIS; RISK FACTORS; SCHIZOPHRENIA;

EID: 0038740717     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200305000-00004     Document Type: Article

References (12)

1. Azzam Z, Krivoy N, Alroy G, Zinder O (1994) Serum creatine kinase levels after a single intramuscular injection-dependence on injection volume. Ann Clin Biochem 31:193-194.
2. Berardi D, Amore M, Keck P, Troia M, Dell'Atti M (1998) Clinical and pharmacological risk factors for neuroleptic malignant syndrome: a case control study. Biol Psychiatry 44:748-754.
3. Caroff S, Mann S, Campbell E (2000) Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann 30:314-321.
4. Davis J, Caroff S, Mann S (2000) Treatment of neuroleptic malignant syndrome. Psychiatr Ann 30:325-331.
5. Hermesh H, Aizenberg D, Weizman A, Lapidot M, Mayor C, Munitz H (1992) Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients. Br J Psychiatry 161:254-257.
6. Hermesh H, Manor I, Shiloh R, Aizenberg D, Benjamini Y, Munitz H, Weizman A (2002) High serum creatine kinase level: possible risk factor for neuroleptic malignant syndrome. J Clin Psychopharmacol 22:252-256.
7. Keck P, McElroy S, Pope H (1991) Epidemiology of neuroleptic malignant syndrome. J Clin Psychiatry 21:148-151.
8. Lazarus A, Mann S, Caroff S (1989) The neuroleptic malignant syndrome and related conditions. Washington, DC: American Psychiatric Press.
9. Levenson J (1985) Neuroleptic malignant syndrome. Am J Psychiatry 142:1137-1145.
10. Meltzer H, Cola P, Parsa M (1996) Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 15:395-405.
11. Meltzer H, Nunkin R, Raferty J (1971) Serum creatine phosphokinase activity in newly admitted psychiatric patients. Arch Gen Psychiatry 24:568-572.
12. Pope H, Keck P, McElroy S (1986) Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 143:1227-1233.